Ashvattha Therapeutics, LLC

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company developing precision nanomedicines based on hydroxyl dendrimer technology to selectively target inflamed tissues in ophthalmology, neurology, and inflammatory diseases. The company's nanomedicines are designed to cross tissue barriers and concentrate in activated cells at sites of inflammation, including a lead candidate in clinical development for diabetic macular edema.